KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:待检查 入排置信度 0.98

Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC.

Andrew J Armstrong, Bhavik J Pandya, Hemant Singh Bhadauria, Arijit Ganguli, Vagia Daki, Ana Moura, Arun A Azad

Future Oncol 21(19) 2459-2469

PMID40654300
PMCIDPMC12330274
DOI10.1080/14796694.2025.2526324
发表日期2025-07-14
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
AI 判定该论文不进入自动 KM 提取:This is a matching-adjusted indirect comparison (MAIC) of two separate trials, not a primary Phase III randomized controlled trial reporting original results.
摘要

摘要

AIMS: To compare the efficacy of enzalutamide + androgen-deprivation therapy (ADT) versus darolutamide + ADT for treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) using a matching-adjusted indirect comparison (MAIC). PATIENTS AND METHODS: Individual patient data from ARCHES (NCT02677896; enzalutamide + ADT, N = 1150) were weighted and adjusted to match published aggregated data on baseline characteristics from ARANOTE (NCT04736199; darolutamide + ADT, N = 669). The MAIC was anchored on the common comparator, placebo + ADT, and provided a (matching-adjusted) hazard ratio (HR) of enzalutamide versus darolutamide. RESULTS: Treatment with enzalutamide + ADT significantly prolonged the primary endpoint of radiographic progression-free survival (HR [95% confidence interval, CI]: 0.54 [0.32-0.93], p = 0.03) and time to castration resistance (HR [95% CI]: 0.57 [0.34-0.94], p = 0.03) compared with darolutamide + ADT (effective sample size: 319). Time to prostate-specific antigen progression (HR [95% CI]: 0.61 [0.29-1.30], p = 0.20) and time to initiation of new antineoplastic therapy (HR [95% CI]: 0.65 [0.34-1.24], p = 0.19) favored enzalutamide over darolutamide, albeit the difference was not statistically significant. CONCLUSIONS: Enzalutamide + ADT showed better efficacy than darolutamide + ADT for treatment of patients with mHSPC. These findings can help inform treatment decisions in clinical practice.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。